GCG and obesity disorder: Individual variability in both the capacity for thermogenesis [135,136] and intolerance to GLP-1–based therapies highlights the need for a personalized approach to obesity pharmacotherapy, emphasizing the importance of developing multiple therapeutic strategies that can be tailored to individual needs and extended to diverse populations, including children.